Deficient brain insulin signalling pathway in Alzheimer's disease and diabetes

Brain glucose metabolism is impaired in Alzheimer's disease (AD), the most common form of dementia. Type 2 diabetes mellitus (T2DM) is reported to increase the risk for dementia, including AD, but the underlying mechanism is not understood. Here, we investigated the brain insulin–PI3K–AKT signalling pathway in the autopsied frontal cortices from nine AD, 10 T2DM, eight T2DM–AD and seven control cases. We found decreases in the levels and activities of several components of the insulin–PI3K–AKT signalling pathway in AD and T2DM cases. The deficiency of insulin–PI3K–AKT signalling was more severe in individuals with both T2DM and AD (T2DM–AD). This decrease in insulin–PI3K–AKT signalling could lead to activation of glycogen synthase kinase‐3β, the major tau kinase. The levels and the activation of the insulin–PI3K–AKT signalling components correlated negatively with the level of tau phosphorylation and positively with protein O‐GlcNAcylation, suggesting that impaired insulin–PI3K–AKT signalling might contribute to neurodegeneration in AD through down‐regulation of O‐GlcNAcylation and the consequent promotion of abnormal tau hyperphosphorylation and neurodegeneration. The decrease in brain insulin–PI3K–AKT signalling also correlated with the activation of calpain I in the brain, suggesting that the decrease might be caused by calpain over‐activation. Our findings provide novel insight into the molecular mechanism by which type 2 diabetes mellitus increases the risk for developing cognitive impairment and dementia in Alzheimer's disease. Copyright © 2011 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

[1]  Akihiko Takashima,et al.  GSK-3 is essential in the pathogenesis of Alzheimer's disease. , 2006, Journal of Alzheimer's disease : JAD.

[2]  Hong Zhang,et al.  Downregulation of IRS-1 protein in thapsigargin-treated human prostate epithelial cells. , 2003, Experimental cell research.

[3]  Huaxi Xu,et al.  Insulin Signaling in Sporadic Alzheimer’s Disease , 2009, Science Signaling.

[4]  I. Grundke‐Iqbal,et al.  Impaired brain glucose metabolism leads to Alzheimer neurofibrillary degeneration through a decrease in tau O-GlcNAcylation. , 2006, Journal of Alzheimer's disease : JAD.

[5]  L. Frölich,et al.  Risk of incident Alzheimer's disease in diabetic patients: a systematic review of prospective trials. , 2009, Journal of Alzheimer's disease : JAD.

[6]  P. Riederer,et al.  Brain insulin system dysfunction in streptozotocin intracerebroventricularly treated rats generates hyperphosphorylated tau protein , 2007, Journal of neurochemistry.

[7]  K. Gerozissis Brain insulin, energy and glucose homeostasis; genes, environment and metabolic pathologies. , 2008, European journal of pharmacology.

[8]  Jiuhong Kang,et al.  Deficiency of a β-arrestin-2 signal complex contributes to insulin resistance , 2009, Nature.

[9]  L. Baki,et al.  Wild-Type But Not FAD Mutant Presenilin-1 Prevents Neuronal Degeneration by Promoting Phosphatidylinositol 3-Kinase Neuroprotective Signaling , 2008, The Journal of Neuroscience.

[10]  M. Brownstein,et al.  Insulin receptors are widely distributed in the central nervous system of the rat , 1978, Nature.

[11]  R. Martins,et al.  Insulin Effects on Glucose Metabolism, Memory, and Plasma Amyloid Precursor Protein in Alzheimer's Disease Differ According to Apolipoprotein‐E Genotype , 2000, Annals of the New York Academy of Sciences.

[12]  R. Nixon,et al.  Widespread activation of calcium-activated neutral proteinase (calpain) in the brain in Alzheimer disease: a potential molecular basis for neuronal degeneration. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[13]  P. Riederer,et al.  Insulin-resistant brain state after intracerebroventricular streptozotocin injection exacerbates Alzheimer-like changes in Tg2576 AbetaPP-overexpressing mice. , 2010, Journal of Alzheimer's disease : JAD.

[14]  K. Jellinger,et al.  Brain insulin and insulin receptors in aging and sporadic Alzheimer's disease , 1998, Journal of Neural Transmission.

[15]  Yasir,et al.  ‘ Protection of synapses against Alzheimer ’ slinked toxins : Insulin signaling prevents the pathogenic binding of A oligomers , 2009 .

[16]  D. Beju,et al.  Preproinsulin I and II mRNAs and insulin electron microscopic immunoreaction are present within the rat fetal nervous system , 1996, Brain Research.

[17]  K. Fukunaga,et al.  Chronic β-AR activation-induced calpain activation and impaired eNOS–Akt signaling mediates cardiac injury in ovariectomized female rats , 2009 .

[18]  E. Masliah,et al.  Defective insulin signaling pathway and increased glycogen synthase kinase‐3 activity in the brain of diabetic mice: Parallels with Alzheimer's disease and correction by insulin , 2008, Journal of neuroscience research.

[19]  Clay B. Holroyd,et al.  Potential roles of insulin and IGF-1 in Alzheimer ’ s disease , 2003 .

[20]  George Perry,et al.  Indices of Metabolic Dysfunction and Oxidative Stress , 2007, Neurochemical Research.

[21]  G. Hart,et al.  O-GlcNAcylation regulates phosphorylation of tau: a mechanism involved in Alzheimer's disease. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[22]  G. Schellenberg,et al.  Effects of intranasal insulin on cognition in memory-impaired older adults: Modulation by APOE genotype , 2006, Neurobiology of Aging.

[23]  野間 治義 Calpain inhibition induces activation of the distinct signalling pathways and cell migration in human monocytes , 2008 .

[24]  Pravir Kumar,et al.  The insulin/Akt signaling pathway is targeted by intracellular beta-amyloid. , 2009, Molecular biology of the cell.

[25]  G. Pasinetti,et al.  Akt/PKB kinase phosphorylates separately Thr212 and Ser214 of tau protein in vitro. , 2003, Biochimica et biophysica acta.

[26]  Veeranna,et al.  Calpain mediates calcium-induced activation of the erk1,2 MAPK pathway and cytoskeletal phosphorylation in neurons: relevance to Alzheimer's disease. , 2004, The American journal of pathology.

[27]  Jianhua Shi,et al.  Reduced O-GlcNAcylation links lower brain glucose metabolism and tau pathology in Alzheimer's disease. , 2009, Brain : a journal of neurology.

[28]  Eva L. Feldman,et al.  How does diabetes accelerate Alzheimer disease pathology? , 2010, Nature Reviews Neurology.

[29]  I. Grundke‐Iqbal,et al.  Mechanisms of tau-induced neurodegeneration , 2009, Acta Neuropathologica.

[30]  W. V. So,et al.  Phosphoinositide signalling links O-GlcNAc transferase to insulin resistance , 2008, Nature.

[31]  H. Braak,et al.  Staging of alzheimer's disease-related neurofibrillary changes , 1995, Neurobiology of Aging.

[32]  J. Ávila,et al.  Calpain‐mediated truncation of GSK‐3 in post‐mortem brain samples , 2009, Journal of neuroscience research.

[33]  J. Wands,et al.  Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease--is this type 3 diabetes? , 2005, Journal of Alzheimer's disease : JAD.

[34]  R. Kalaria,et al.  Neurodegenerative disease: Diabetes, microvascular pathology and Alzheimer disease , 2009, Nature Reviews Neurology.

[35]  G. Schellenberg,et al.  Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-beta in memory-impaired older adults. , 2008, Journal of Alzheimer's disease : JAD.

[36]  S. Craft,et al.  Rosiglitazone attenuates learning and memory deficits in Tg2576 Alzheimer mice , 2006, Experimental Neurology.

[37]  A D Roses,et al.  Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease , 2006, The Pharmacogenomics Journal.

[38]  H. Wiśniewski,et al.  Abnormal phosphorylation of the microtubule-associated protein? (tau) in Alzheimer cytoskeletal pathology , 1987 .

[39]  E. Braak,et al.  Distribution, Levels, and Activity of Glycogen Synthase Kinase‐3 in the Alzheimer Disease Brain , 1997, Journal of neuropathology and experimental neurology.

[40]  K. Tomizawa,et al.  Truncation and Activation of Calcineurin A by Calpain I in Alzheimer Disease Brain* , 2005, Journal of Biological Chemistry.

[41]  L. Feig,et al.  The R-Ras GTPase Mediates Cross Talk between Estrogen and Insulin Signaling in Breast Cancer Cells , 2006, Molecular and Cellular Biology.

[42]  William A Banks,et al.  The source of cerebral insulin. , 2004, European journal of pharmacology.

[43]  P. Scheltens,et al.  Risk of dementia in diabetes mellitus: a systematic review , 2006, The Lancet Neurology.

[44]  U. Tuor,et al.  Intranasal insulin prevents cognitive decline, cerebral atrophy and white matter changes in murine type I diabetic encephalopathy. , 2008, Brain : a journal of neurology.

[45]  I. Grundke‐Iqbal,et al.  Brain glucose transporters, O‐GlcNAcylation and phosphorylation of tau in diabetes and Alzheimer’s disease , 2009, Journal of neurochemistry.

[46]  B. Posner,et al.  Insulin-binding sites in the rat brain: in vivo localization to the circumventricular organs by quantitative radioautography. , 1979, Endocrinology.

[47]  J. Ávila,et al.  GSK-3 inhibitors for Alzheimer’s disease , 2007, Expert review of neurotherapeutics.

[48]  M. Reger,et al.  Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. , 2005, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[49]  Fei Liu,et al.  Down‐regulation of cAMP‐dependent protein kinase by over‐activated calpain in Alzheimer disease brain , 2007, Journal of neurochemistry.

[50]  R. Ravid,et al.  Activation of Akt/PKB, increased phosphorylation of Akt substrates and loss and altered distribution of Akt and PTEN are features of Alzheimer's disease pathology , 2005, Journal of neurochemistry.

[51]  S. M. Sumi,et al.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) , 1991, Neurology.

[52]  Alberto Pupi,et al.  Brain Glucose Hypometabolism and Oxidative Stress in Preclinical Alzheimer's Disease , 2008, Annals of the New York Academy of Sciences.

[53]  H. Wiśniewski,et al.  Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[54]  A. Bensadoun,et al.  Assay of proteins in the presence of interfering materials. , 1976, Analytical biochemistry.

[55]  I. Grundke‐Iqbal,et al.  Dysregulation of insulin signaling, glucose transporters, O-GlcNAcylation, and phosphorylation of tau and neurofilaments in the brain: Implication for Alzheimer's disease. , 2009, The American journal of pathology.

[56]  Xiongwei Zhu,et al.  Insulin is a two-edged knife on the brain. , 2009, Journal of Alzheimer's disease : JAD.

[57]  G. Hart,et al.  Elevated nucleocytoplasmic glycosylation by O-GlcNAc results in insulin resistance associated with defects in Akt activation in 3T3-L1 adipocytes , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[58]  Simon Lovestone,et al.  The GSK3 hypothesis of Alzheimer's disease , 2008, Journal of neurochemistry.

[59]  R. Schechter,et al.  Neuronal synthesized insulin roles on neural differentiation within fetal rat neuron cell cultures. , 2001, Brain research. Developmental brain research.

[60]  Xiongwei Zhu,et al.  Insulin signaling, diabetes mellitus and risk of Alzheimer disease. , 2005, Journal of Alzheimer's disease : JAD.

[61]  C. Gong,et al.  Concurrent alterations of O‐GlcNAcylation and phosphorylation of tau in mouse brains during fasting , 2006, The European journal of neuroscience.

[62]  W. Klein,et al.  Protection of synapses against Alzheimer's-linked toxins: Insulin signaling prevents the pathogenic binding of Aβ oligomers , 2009, Proceedings of the National Academy of Sciences.